Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Prometheus Biosciences, Inc. - Common Stock (NQ:RXDX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 199.92 (9)
Ask (Size) 199.99 (7)
Prev. Close 199.92
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 41,700,063
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Shares of Exscientia Jumped on Wednesday
The company may be riding the wave of an AI healthcare boom. 
Via The Motley Fool
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga

Performance

More News

Read More
Why Shares of Ventyx Biosciences Rose Monday
Via The Motley Fool
Is Merck Stock a Top Buy Right Now?
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
3 Innovative Growth Stocks to Buy for Next-Gen Profits
Via InvestorPlace
RXDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Prometheus Biosciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
From Kahn Swick & Foti, LLC
Via Business Wire
3 Undervalued Pharma Stocks to Buy for High Total Returns
Via InvestorPlace
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
Via Benzinga
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Via Investor's Business Daily
Merck Makes a Bold Move That Could Transform Its Business
Via The Motley Fool
3 Biotechs That Might Get Bought Out in 2023
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Via The Motley Fool
PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
From Kahn Swick & Foti, LLC
Via Business Wire
Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review
Via Investor's Business Daily
Why Prometheus Biosciences Stock Is Skyrocketing This Week
Via The Motley Fool
Why This Nasdaq Stock Caught Fire This Week
Via The Motley Fool

Frequently Asked Questions

Is Prometheus Biosciences, Inc. - Common Stock publicly traded?
Yes, Prometheus Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Prometheus Biosciences, Inc. - Common Stock trade on?
Prometheus Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Prometheus Biosciences, Inc. - Common Stock?
The ticker symbol for Prometheus Biosciences, Inc. - Common Stock is RXDX on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.